Summary & Overview
HCPCS J7605: Arformoterol Inhalation Solution, Unit Dose 15 mcg
HCPCS Level II code J7605 represents arformoterol inhalation solution, an FDA-approved, non-compounded unit-dose bronchodilator (15 micrograms) administered through durable medical equipment. This code is used to bill for the medication product when provided for nebulizer-based maintenance therapy. Nationally, accurate coding for inhaled long-acting bronchodilators is important for appropriate medication reimbursement, patient access to home nebulizer therapies, and tracking utilization of respiratory specialty drugs.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for arformoterol use, the typical sites of service where this HCPCS product code applies, and the payment and billing considerations that commonly arise for unit-dose DME-delivered inhalation solutions. The publication outlines benchmarks and policy-relevant items such as coverage considerations, coding clarity for DME-administered drugs, and common billing modifiers and service-line attributes. Data not available in the input will be noted where applicable. This national-level summary is intended to inform billing staff, revenue cycle professionals, and policy analysts about the clinical role and billing context of J7605 without prescribing clinical care or specific billing actions.
Billing Code Overview
HCPCS Level II code J7605 describes arformoterol inhalation solution, FDA-approved final product, non-compounded, administered through durable medical equipment (DME), unit dose form, 15 micrograms. This drug is a long-acting bronchodilator formulation delivered via inhalation solution intended for patients requiring nebulized maintenance therapy.
-
Service type: Drug administration via DME (nebulizer-delivered inhalation solution)
-
Typical site of service: Home health or other outpatient settings where patients use durable medical equipment for inhalation therapy
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old with chronic obstructive pulmonary disease (COPD) who presents to a durable medical equipment (DME)-affiliated outpatient infusion/respiratory clinic for administration of inhaled arformoterol nebulizer solution. The patient has a long history of inhaled bronchodilator therapy and requires a unit-dose, FDA-approved arformoterol product (J7605) delivered via a facility-supplied nebulizer. The clinical workflow begins with verification of the prescription and current medication list by a respiratory therapist or nurse, confirmation of patient identity and allergies, and assessment of baseline vitals and lung auscultation. The therapist assembles the DME nebulizer, prepares the single-use 15 microgram unit-dose vial per manufacturer instructions, and administers the inhalation solution while monitoring oxygen saturation and heart rate. Post-administration observation includes reassessment of respiratory status, documentation of response and any adverse effects (tachycardia, tremor, paradoxical bronchospasm), and billing staff applying J7605 for the medication administered along with the appropriate place-of-service and service modifiers. Typical sites of service include outpatient DME supplier locations, hospital outpatient departments, ambulatory care clinics, and skilled nursing facilities where DME nebulizer administration is provided. Payers involved commonly include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|